cover image - Psychiatric Drugs Explained,Elsevier E-Book on VitalSource, 7th Edition
ISBN: 9780702083921
Copyright: 2023
Publication Date: 05-20-2022
Page Count: 356
Imprint: Elsevier
List Price: $31.99

Psychiatric Drugs Explained,Elsevier E-Book on VitalSource, 7th Edition

by David Healy, MD, FRCPsych

Elsevier eBook on VitalSource

cover image - Psychiatric Drugs Explained,Elsevier E-Book on VitalSource, 7th Edition
ISBN: 9780702083921
Copyright: 2023
Publication Date: 05-20-2022
Page Count: 356
Imprint: Elsevier
List Price: $31.99
Was $31.99

Now $28.15

Or $0.00 with a valid access code

Psychiatric Drugs Explained offers a wealth of evidence-based information on psychiatric drugs in an easy-to-use format that can be quickly referenced in the clinical setting.

Written by internationally recognised author Dr David Healy, the book provides a comprehensive review of drug effects, action and side-effects. There is an emphasis on the lived experience of patients, providing the reader with a sense of what the adverse effects of drugs might feel like to those who use them.

A reader-friendly approach and clear layout, with information organised by disorder, make this popular title accessible and useful not only to nursing staff, but to all members of the multidisciplinary team.

    • Quick reference guide suitable for all members of the multidisciplinary team
    • Helpful boxes on user issues make potential complications easy to spot
    • Distinctive, reader-friendly style helps the reader understand the benefits and impacts of psychotropic drugs
    • New topics include management of dependence disorders, stimulants and drugs for children, cognitive impairment and sleep disorders
    • The only book with detailed coverage of the sexual side effects of psychiatric drugs and the abusive prescribing of prescription drugs
  • Section 1 Management of the psychoses
    1 The antipsychotics
    2. Antipsychotic side effects and their management

    Section 2 Management of depression
    3. The antidepressants
    4. Side effects of antidepressants

    Section 3 Management of bipolar disorders
    5. Management of acute bipolar disorder
    6. Mood-stabilisers

    Section 4 Stimulants & Drugs for children
    7. Stimulants & Drugs for children

    Section 5 Management of anxiety
    8. The anxiety disorders
    10. Benzodiazepine anxiolytics
    11. Anxiolysis and the serotonin system
    12. Beta-blockers and anxiety

    Section 6 Management of sleep disorders and insomnia
    13. Sleep disorders and insomnia
    14. Non-pharmacological management of insomnia
    15. Hypnotics
    16. Sedatives

    Section 7 Management of cognitive impairment
    17. Cognitive enhancement and the dementias
    18. Cognitive enhancement and neuroprotection

    Section 8 Management of sexual difficulties
    19. The range of sexual difficulties
    20. Effects of drugs on aspects of sexual functioning

    Section 9 Management of dependence and withdrawal
    21. Dependence & Withdrawal
    22. Dependence & Craving
    23. Dependence & Protracted Withdrawal

    Section 10 Consent, abuse and liability
    24. Consent
    25. Pharmacological abuse

    Section 11 The marketing of tranquillity
    26. The ethical industry
    27. Evidence-biased care
    28. Marketing & Risk
    29. From healthcare to pharmageddon
  • David Healy, MD, FRCPsych, Director, North Wales Department of Psychological Medicine, College of Medicine, Cardiff University, Bangor, UK
    • Ways of Reading
      • The appearance of the text and page layout can be modified according to the capabilities of the reading system (font family and font size, spaces between paragraphs, sentences, words, and letters, as well as color of background and text)
      • This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation
      • No information about nonvisual reading is available
    • Conformance
      • No information is available
    • Navigation
      • Table of contents to all chapters of the text via links
      • Page list to go to pages from the print source version
    • Rich Content
      • No information is available
    • Hazards
      • No information is available
    • Product Content
      • No information is available
    • Legal Considerations
      • No information is available
    • Additional Accessibility Information
      • Page breaks included from the original print source
      • For readers with color vision deficiency, use of color (e.g., in diagrams, graphics and charts, in prompts, or on buttons inviting a response) is not the sole means of graphical distinction or of conveying information
      • E-publication includes basic navigation (usually less detailed than TOC-based navigation)
      • Where links, controls or buttons are included in the content, the purpose or functionality of each link, control or button is apparent from the associated text alone - or where it is unclear, separate link, control or button descriptions are provided
      • All (or substantially all) textual matter is arranged in a single logical reading order (including text that is visually presented as separate from the main text flow, e.g., in boxouts, captions, tables, footnotes, endnotes, citations, etc.). Non-textual content is also linked from within this logical reading order. (Purely decorative non-text content can be ignored).
      • The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.
Was $31.99

Now $28.15

Or $0.00 with a valid access code